Beren Therapeutics Bolsters IP Portfolio with Eight New U.S. Patents for Cyclodextrin Therapies
Event summary
- Beren Therapeutics secured eight new U.S. patents related to its proprietary derivatized cyclodextrins, including adrabetadex.
- The company's total U.S. patent portfolio now exceeds 30 issued patents.
- These patents cover compositions, formulations, manufacturing processes, biomarkers, and treatment methods for Niemann-Pick disease, type C (NPC).
- Adrabetadex is under FDA review with a PDUFA target action date of November 17, 2026.
The big picture
Beren Therapeutics' expansion of its IP estate underscores its commitment to cyclodextrin-based therapies for rare diseases like NPC. The strategic move comes as the company awaits a critical FDA decision on adrabetadex, highlighting the intersection of patent protection and regulatory approval in the biotech sector.
What we're watching
- Regulatory Milestones
- The pace at which the FDA reviews adrabetadex for NPC, with a decision expected by November 17, 2026.
- IP Strategy
- How Beren Therapeutics will leverage its expanded IP portfolio to defend market position and attract partnerships.
- Clinical Development
- Whether the company can sustain momentum in developing next-generation cholesterol trafficking therapeutics beyond NPC.
Related topics